

[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI
[ Wed, Feb 07th 2024
] - WOPRAI

[ Tue, Feb 06th 2024
] - WOPRAI
[ Tue, Feb 06th 2024
] - WOPRAI
[ Tue, Feb 06th 2024
] - WOPRAI
[ Tue, Feb 06th 2024
] - WOPRAI
[ Tue, Feb 06th 2024
] - WOPRAI
[ Tue, Feb 06th 2024
] - WOPRAI
Andrew Fein Maintained (VRTX) at Strong Buy with Increased Target to $457 on, Feb 6th, 2024
Andrew Fein of HC Wainwright & Co., Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy with Increased Target from $397 to $457 on, Feb 6th, 2024.
Andrew has made no other calls on VRTX in the last 4 months.
There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 4 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- William Pickering of "Bernstein" Downgraded from Buy to Hold on, Friday, February 2nd, 2024
- Naz Rahman of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, January 31st, 2024
- Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023
These are the ratings of the 5 analyists that currently disagree with Andrew
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $508 on, Wednesday, January 31st, 2024
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $559 on, Wednesday, January 31st, 2024
- Whitney Ijem of "Canaccord Genuity" Downgraded from Hold to Strong Sell and Increased Target to $379 on, Wednesday, January 24th, 2024
- Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
- Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023
Contributing Sources